NCT06541756 Fibrine Clot-augmented Repair of Longitudinal Meniscus Tears
| NCT ID | NCT06541756 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ankara City Hospital Bilkent |
| Condition | Meniscus Tear |
| Study Type | INTERVENTIONAL |
| Enrollment | 120 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2028-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 120 participants in total. It began in 2024-07-25 with a primary completion date of 2028-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Longitudinal meniscal tears are a type of meniscal injury characterized by a displaced fragment of the meniscus that flips over into the joint, often resembling a buckle or handle. These tears typically occur in the medial meniscus and are often associated with traumatic knee injuries, particularly in athletes. The displaced meniscal fragment can cause mechanical symptoms such as locking, clicking, or catching of the knee, as well as pain and swelling. If not properly treated, buckle-handle meniscal tears can lead to further complications, including chronic knee instability, increased risk of osteoarthritis, and persistent joint pain.Repairing a longitudinal meniscal tear offers several advantages over partial meniscectomy, particularly in preserving knee function and preventing long-term complications. Meniscal repair aims to restore the integrity of the meniscus, which plays a crucial role in load distribution, shock absorption, and joint stability. Utilizing a fibrin clot during the repair of a buckle-handle meniscal tear can enhance the healing process and improve surgical outcomes. Fibrin clots act as a biological scaffold, promoting tissue regeneration by providing a matrix that facilitates cellular migration and proliferation. The purpose of this study was to compare longitudinal meniscal tear repair reinforced with fibrin clot with routine end-to-end repair in a prospective randomized controlled trial.
Eligibility Criteria
Inclusion Criteria: * Presenting with a painful meniscus (lateral or medial) longitudinal tear * Being between the ages of 18 and 50 * Not having undergone surgery on the same knee before * Having an MRI taken at the end of the 1st year post-surgery Exclusion Criteria: * Having additional collateral ligamentous damage along with the meniscus tear (such as MCL or LCL) * Incomplete clinical scores at the end of the study * A history of previous surgery on the same knee * Having an active infection * Not having a control MRI at the end of the 1st year
Contact & Investigator
Enejd Veizi, MD
PRINCIPAL INVESTIGATOR
Ankara City Hospital Bilkent
Frequently Asked Questions
Who can join the NCT06541756 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 50 Years, studying Meniscus Tear. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06541756 currently recruiting?
Yes, NCT06541756 is actively recruiting participants. Contact the research team at dr.nad89@hotmail.com for enrollment information.
Where is the NCT06541756 trial being conducted?
This trial is being conducted at Ankara, Turkey (Türkiye), Ankara, Turkey (Türkiye).
Who is sponsoring the NCT06541756 clinical trial?
NCT06541756 is sponsored by Ankara City Hospital Bilkent. The principal investigator is Enejd Veizi, MD at Ankara City Hospital Bilkent. The trial plans to enroll 120 participants.